MedTrace Logo

Clinical Pharmacology Study of MT-3534 in Healthy Adult Male Volunteers

NCT06482346 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2025-08-05

No results posted yet for this study

Summary

This study is planned to investigate the safety, tolerability, and pharmacokinetics when a single intravenous dose of MT-3534 or a placebo is given to healthy adult male volunteers.

Conditions

  • Healthy Adult Male Volunteers

Interventions

BIOLOGICAL

MT-3534

Solution for infusion; Intravenous (IV)

BIOLOGICAL

Placebo

Solution for infusion; Intravenous (IV)

Sponsors & Collaborators

  • Mitsubishi Tanabe Pharma Corporation

    lead INDUSTRY

Principal Investigators

  • General Manager · Mitsubishi Tanabe Pharma Corporation

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-08-09
Primary Completion
2025-07-09
Completion
2025-07-09

Countries

  • Japan

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06482346 on ClinicalTrials.gov